This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tekmira Pharmaceuticals To Webcast Presentation At The Piper Jaffray Health Care Conference

VANCOUVER, British Columbia, Nov. 24, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today that the Company's President and Chief Executive Officer, Dr. Mark J. Murray, will present at the Piper Jaffray 22nd Annual Health Care Conference on Tuesday November 30, 2010 at 4:30 pm ET at the New York Palace Hotel in New York City. A webcast of the presentation will be available and can be accessed on the Company's website, www.tekmirapharm.com .

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com . Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8319
CONTACT:  The Equicom Group 
          Investors 
          Adam Peeler
          416-815-0700 x 225 
          apeeler@equicomgroup.com

          Tekmira Pharmaceuticals
          Investors
          Ian Mortimer, Executive Vice President and
           Chief Financial Officer 
          604-419-3200   

          Longview Communications Inc.
          Media 
          David Ryan 
          604-694-6031 
          dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs